首页> 外文期刊>Evidence-based ophthalmology >THE VALUE COMPONENT OF EVIDENCE-BASED MEDICINE: THE UTILITY ANALYSIS OF EARLY VERSUS LATE CORTICOSTEROID TREATMENT FOR GIANT CELL ARTERITIS
【24h】

THE VALUE COMPONENT OF EVIDENCE-BASED MEDICINE: THE UTILITY ANALYSIS OF EARLY VERSUS LATE CORTICOSTEROID TREATMENT FOR GIANT CELL ARTERITIS

机译:循证医学的价值要素:早期抗晚期糖皮质激素治疗巨细胞性动脉炎的实用性分析

获取原文
获取原文并翻译 | 示例
           

摘要

It is the philosophy of Evidence-based Eye Care that evidence-based medicine should provide the foundation for knowledge which will allow practitioners to provide the highest quality of medicine for patients. Although, the knowledge of a numerical or statistical change is critical, this information must be taken to another level to ascertain the true value of evidence-based discoveries to patients and society. As an example, it was shown in the Branch Retinal Vein Occlusion Study that laser treatment of macular edema occurring secondary to retinal vein obstruction yields a long-term mean visual acuity of 20/40-20/50, as compared with a mean visual acuity of 20/70 in the untreated group. But equally as important is the question, "What does this mean for the quality of life of my patient?"
机译:循证眼保健的哲学是,循证医学应提供知识的基础,使从业者可以为患者提供最高质量的医学。尽管对数值或统计变化的了解至关重要,但必须将这些信息带入另一个层次,才能确定基于证据的发现对患者和社会的真正价值。例如,在分支视网膜静脉阻塞研究中显示,与平均视力相比,激光治疗视网膜静脉阻塞继发的黄斑水肿产生的长期平均视力为20 / 40-20 / 50未经治疗的组为20/70。但同样重要的问题是:“这对我的患者的生活质量意味着什么?”

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号